antifungal susceptibility testing
SusceptibilityAPX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference MethodAPX001A is the active moiety of the first-in-class drug candidate APX001. So far, most susceptibility testing studies have examined ≤30 isolates/species, and only one used the EUCAST method.
- SusceptibilityEmergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India
This prospective study shows that the rate of azole-resistant Aspergillus fumigatus (ARAF) in an immunocompromised Indian patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This low rate supports the continued use of voriconazole as the first line of treatment.
- Mechanisms of ResistanceUnderstanding Echinocandin Resistance in the Emerging Pathogen Candida auris
- Experimental TherapeuticsIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris